1. A donanemab (LY3002813) prevention study in participants with Alzheimer's disease (TRAILBLAZER-ALZ 3). https://clinicaltrials.gov/ct2/show/NCT05026866 (accessed May 12, 2022).
2. A study to evaluate the efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer's disease (AD) (SKYLINE). https://clinicaltrials.gov/ct2/show/NCT05256134 (accessed May 12, 2022).
3. Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf, pages 19–21 (accessed May 12, 2022).
4. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States;Brookmeyer;Alzheimers Dement,2019
5. Clinical trial of solanezumab for older individuals who may be at risk for memory loss (A4). https://clinicaltrials.gov/ct2/show/NCT02008357 (accessed May 12, 2022).